-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, W0LHaEbdqBxSZ8bqEuQ9AW1Jculh0sX4XP/1++KYy4KrZa94UjU4hHtUyF9m42Uq MiiAksKYjmMzrBIaGSYVTw== 0001454982-11-000008.txt : 20110118 0001454982-11-000008.hdr.sgml : 20110117 20110118183823 ACCESSION NUMBER: 0001454982-11-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110118 FILED AS OF DATE: 20110118 DATE AS OF CHANGE: 20110118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KOLTERMAN ORVILLE G CENTRAL INDEX KEY: 0001236394 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 11534202 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS INC STREET 2: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0303 4 2011-01-18 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001236394 KOLTERMAN ORVILLE G 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 SVP, Chief Medical Officer Common Stock 2011-01-18 4 M 0 2500 11.125 A 154139 D Common Stock 2011-01-18 4 S 0 2500 15 D 151639 D Common Stock 4815 I by ESOP Non-Qualified Stock Option (right to buy) 11.125 2011-01-18 4 M 0 2500 15 D 2011-03-08 Common Stock 2500 7850 D The sale was affected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. 25% of shares vested one year from date of grant and the remainder vested monthly over the next three years becoming fully vested four years from date of grant. By: /s/James R. Oehler, Attorney-in-Fact For: Orville G. Kolterman 2011-01-18 -----END PRIVACY-ENHANCED MESSAGE-----